Maverick Therapeutics is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/ Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
There is no investment information
No recent news or press coverage available for Maverick Therapeutics.